Introduction {#S1}
============

Obstructive sleep apnea (OSA) is a clinical condition characterized by recurrent episodes of partial or complete upper airway obstructions during sleep, promoting intermittent hypoxia and sleep fragmentation ([@B1]). The prevalence of OSA among patients with end-stage renal disease (ESRD) varies according to the diagnostic criteria used and whether it was based on questionnaires (reaching 50--80%) ([@B2], [@B3]) or polysomnography (PSG) (16--46%) ([@B4], [@B5]) and is associated with mortality among patients on hemodialysis (HD) ([@B6], [@B7]).

Several factors contribute to the pathophysiology of OSA in patients with ESRD, such as uremia and associated comorbidities in ESRD ([@B8]). Volume overload, which is commonly observed in these patients, plays a pivotal role in this context. It leads to edema formation in upper airways and, consequently, to pharyngeal narrowing ([@B9], [@B10]). Hypervolemia also augments overnight spontaneous fluid shift, which occurs as the fluid accumulated in the legs during the day moves rostrally during bedtime, while on recumbent position. This is associated with overnight increase in neck circumference (NC) and the severity of OSA, not only in patients with OSA from the general population ([@B11]) but also particularly in patients with fluid retaining states, such as congestive heart failure (CHF) ([@B12]) and ESRD ([@B4]).

Avoiding fluid accumulation in the legs during the day by wearing compression stockings (CS) is an option to attenuate the overnight fluid shift as the compression exerted increases the pressure applied to the interstitium, thus reducing fluid filtration from capillaries in the legs ([@B13]). It has been demonstrated that wearing CS during the day attenuates OSA ([@B14]--[@B16]). It is still unclear why avoiding leg swelling leads to lower obstructive respiratory events during the night. A plausible mechanism is that the hydraulic pressure exerted upward leads to fluid retention in the trunk, thus increasing daytime diuresis and, consequently, lowering total body water (TBW). The effects associated with the wearing of CS in relation to fluid redistribution and severity of OSA in oliguric and anuric patients are unknown.

On the other hand, the standard treatment for OSA, the continuous positive airway pressure (CPAP), avoids airway collapsibility, by mechanically exerting pressure on airways, thus preventing some critical anatomic points to collapse, such as the retropalatal region of the oropharynx ([@B17]). However, another consequence of such pressure is avoiding fluid accumulation in upper airways, once relatively small amounts of fluid (100--200 ml) enlarge airway soft tissues and may cause airway constriction ([@B18]). Even though CPAP may reduce such local edema, it is not clear whether such local and "downward" pressure interferes in overall body fluid shift.

Therefore, this randomized crossover clinical trial was conducted to evaluate the short-term impact of wearing CS and CPAP on the severity of OSA and fluid redistribution between legs and trunk in a sample of oliguric or anuric patients on HD. We also evaluated the impact of these interventions on overnight changes in NC. We hypothesized that CS would interfere in overnight rostral fluid shift from the legs, with consequent improvement of OSA, while CPAP would act locally on upper airways and improve OSA regardless of fluid shift.

Materials and Methods {#S2}
=====================

Study Design {#S2-1}
------------

This was a randomized crossover trial that compared the effect of CS and CPAP on apnea--hypopnea index (AHI), NC, and fluid redistribution in oliguric or anuric patients on HD. OSA was screened by Berlin questionnaire and further confirmed (defined as AHI \> 5 events/h) by a baseline PSG. Patients were randomly assigned for another PSG either for CPAP titration or after wearing CS for 1 week during daytime and then crossed over to the other treatment. Randomization was done by block, with two possibilities: baseline-CS-CPAP or baseline-CPAP-CS. Patients had not been previously treated with CPAP or CS before study entry. The study was approved by the local Ethics Committee for Research Project Analysis---Cappesq (\#11302/2013) and registered in Clinical Trials platform (NCT02503215). All patients have signed written informed consent.

Subjects {#S2-2}
--------

Patients were recruited from the HD service of the Hospital das Clínicas, Universidade de São Paulo, Brazil. Inclusion criteria were as follows: (1) dialysis vintage of at least 6 months; (2) age between 18 and 70 years; (3) diagnosis of OSA by overnight PSG; and (4) residual diuresis lower than 500 ml/day. Exclusion criteria were as follows: (1) diagnosed heart failure, atrial fibrillation, chronic obstructive pulmonary disease or neoplasia; (2) inferior limbs prosthesis or amputation; (3) current CPAP treatment; (4) negative screening by the Berlin scale; (5) thrombosis of superior vena cava; (6) presence of ascites or pleural effusion. During the study, there was no change in any prescribed medication, including antihypertensive drugs and erythropoietin-stimulating agents.

Hemodialysis {#S2-3}
------------

All dialysis were performed using 4008S machines and high-flux polysulfone membranes from Fresenius Medical Care™ (Bad Homburg, Germany). The prescription was according to the attending nephrologists with no interference in the duration of the sessions and ultrafiltration rates during the study protocol. Routine exams performed regularly in our service were assessed and included. Dialysis dose, assessed by standard *Kt*/*V*, where *K* = dialyzer clearance, *t* = time, and *V* = volume of body water. We also assessed annual echocardiogram data, which provided the following variables: ejection fraction calculated by Teichholz's formula and left ventricular mass index (LVMI).

Berlin Questionnaire and Epworth Sleepiness Scale (ESS) {#S2-4}
-------------------------------------------------------

Berlin questionnaire was administered to all patients as screening for OSA ([@B19]). Patients at low risk for OSA according to this scale were excluded from study protocol. ESS ([@B20]) was applied before PSG exam in two moments: at baseline and after wearing CS for 1 week.

Polysomnography {#S2-5}
---------------

Overnight PSG was performed using the Embla™ S 4500 (Embla Systems, Inc., Broomfield, CO, USA) at the Sleep Laboratory of Hospital das Clínicas. Sleep stages and arousals were scored according to standard techniques ([@B21]). All subjects slept with a single pillow on a flat bed. Thoracoabdominal motion was monitored by respiratory inductance plethysmography and nasal airflow by nasal pressure cannulas ([@B22]), while arterial oxyhemoglobin saturation was continuously monitored by pulse oximetry. Obstructive apneas were defined as cessation of airflow for at least 10 s, while hypopnea was defined as a 50% or greater reduction in airflow from baseline, yet remaining above 0 for more than 10 s with thoracoabdominal motion or flow limitation on the nasal pressure tracing associated with either an oxygen desaturation of greater than 3% or an arousal. Central apneas or hypopneas were diagnosed by the absence of such thoracoabdominal movements. AHI was calculated as the total overnight number of obstructive and central apneas and hypopneas divided by total sleep time (TST). Sleep efficiency was calculated as percentage of TST of the time spent in bed after lights out. Both REM sleep and all stages of non-REM sleep were quantified as a percentage of TST. Electromyographic recordings of leg movements from the anterior tibialis muscles by standard surface electrodes allowed assessment of periodic leg movement index (PLMI). Patients were allowed to wake up freely. All sleep studies were scored by the same physician, who was blinded to the use of CS or baseline and to the measurements of leg fluid volume and NC.

Each patient underwent the baseline, and the two other patients underwent PSG exams in the same interdialytic interval, specifically in the same weekday.

Body Fluid Volumes, Body Weight, NC, and Residual Urine Output {#S2-6}
--------------------------------------------------------------

Segmental tetrapolar bioelectrical impedance (BIS) was performed in all patients while recumbent, before and after each PSG exam, by the multifrequency InBody™ S10 (Biospace Co., Ltd., Korea) device, which allowed assessment of the following parameters: TBW, lower limbs total water content (LLW), lower limbs extracellular water content (ecLLW), trunk total water content (TW), and trunk extracellular water content (ecTW). NC was measured above the cricothyroid cartilage with a tape measure just before bedtime and right after waking in the morning; body weight was verified in the same period. We considered "excess weight" the amount above the dry weight (defined as a routine by the dialysis team and commonly achieved at the end of dialysis session). Residual urinary output was assessed using a questionnaire, and patients should be either anuric or have no more than two episodes of diuresis per day, with an estimated volume lower than 200 ml each (\<500 ml/day). Overnight variations of studied parameters were defined as delta, which represents the nocturnal variation (difference between measurements in the evening, just before the PSG and that obtained in the next morning).

CPAP Titration {#S2-7}
--------------

All subjects underwent PSG for CPAP titration, with ResMed S9 Escape™ (ResMed Ltd., Australia) CPAP device, which was manually titrated by the same technician to determine the optimal pressure level according AASM ([@B23]). The lowest CPAP pressure (4 cmH~2~O) was initially applied to all patients and increased progressively as needed. The optimal CPAP pressure was determined when the pressure could eliminate apnea, hypopnea, desaturation, arousals, and snoring in supine position.

Compression Stockings {#S2-8}
---------------------

Patients were fitted with appropriately sized below-the-knee Sigvaris™ (Sigvaris Corp., Switzerland, manufactured by Sigvaris Brazil) CS, exerting an ankle pressures between 20 and 30 mmHg. Patients were instructed to wear CS for 1 week, immediately after wake up and removing them just before going to sleep. On the last day of this period, PSG was repeated.

Outcome Measures {#S2-9}
----------------

The primary outcome was the overnight fluid redistribution assessed in the three PSG exams. Secondary outcomes were variation of NC and change in AHI in PSG exam after CPAP titration and after wearing CS in comparison to baseline.

Statistical Analysis {#S2-10}
--------------------

Continuous variables were expressed as mean ± SD or median (25 and 75 percentiles) according to normal or abnormal data distribution, respectively. Categorical variables were expressed as proportions. Repeated measures analyses of variance or Friedman's test were used to compare changes in variables among baseline, CPAP, or CS exams, as appropriate. For between-group analyses, Dunn's test was applied when null hypothesis was rejected. Statistical analyses were performed by SPSS 20 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). The sample size was calculated assuming a 35% reduction in AHI after wearing CS, based on a previous randomized trial ([@B15]), with a two-tailed α of 0.05 and β of 80%. The resulting sample size was 14 patients.

Results {#S3}
=======

Baseline Characteristics, Enrollment, and Dialysis Parameters {#S3-1}
-------------------------------------------------------------

From January to December 2015, 111 patients from HD service were screened, of whom 18 underwent PSG and 14 completed the study protocol, as depicted in Figure [1](#F1){ref-type="fig"}. The baseline characteristics of the studied population are described in Table [1](#T1){ref-type="table"}. Overall, patients were middle aged, mainly men, and Caucasian. Dialysis efficiency, assessed by standard *Kt*/*V*, was within recommended targets ([@B24]). LVMI was within normal range (\<95 g/m^2^ in women and \<115 g/m^2^ in men) in eight patients (57%). The majority of patients were anuric, and none of them were taking any diuretic. Time from baseline PSG to the second exam was 64 (26, 242) days and from the second to the third PSG exam was 10 (7, 21) days.

![**Study flow**. CHF, congestive heart failure; LL, lower limb; AHI, apnea--hypopnea index; CS, compression stockings.](fmed-04-00057-g001){#F1}

###### 

**Cohort characteristics**.

  Characteristic                  *N* = 14
  ------------------------------- -------------------
  Age (years)                     53 ± 9
  Gender (% male)                 57
  Race (% Caucasian)              86
  Body mass index (kg/m^2^)       29.7 ± 6.8
  Dialysis vintage (months)       32 (19; 109)
  Anuria (%)                      64
  Standard *Kt/V*                 2.14 ± 0.54
  Blood flow (ml/min)             350 (337; 350)
  Dialyzate flow (ml/min)         714 ± 140
  Dialysis duration (h/session)   4 (3.8; 4)
  Arteriovenous fistula (%)       86
  Arterial hypertension (%)       57
  Diabetes mellitus (%)           14
  Smoking habitus (%)             14
  Ejection fraction (%)           64 ± 3
  LVMI (g/m^2^)                   119 ± 38
  ACE inhibitors (%)              50
  CCB (%)                         21
  β-Blockers (%)                  21
  Creatinine (mg/dl)              11.0 ± 2.9
  Albumin (mg/dl)                 4.15 ± 0.53
  Hemoglobin (g/dl)               11.8 ± 1.0
  PTH (pg/ml)                     379 (311; 614)
  VitD (ng/ml)                    33.5 (22.7; 37.5)
  Ionized calcium (mg/dl)         4.8 ± 0.3
  Phosphorus (mg/dl)              5.5 ± 1.4

*LVMI, left ventricular mass index; ACE, angiotensin-converting enzyme; CCB, calcium channel blockers; VitD, vitamin D*.

*Data are presented as mean ± SD or percentage*.

Sleep Data {#S3-2}
----------

Epworth sleepiness scale was performed at baseline and after wearing CS and neither changed: 10.2 ± 4.6 vs. 8.4 ± 5.2, respectively, *p* = 0.132. Table [2](#T2){ref-type="table"} shows PSG data. Patients slept on average of 5--6 h, with 75% sleep efficiency.

###### 

**Sleep study data in the three moments of study**.

  Sleep variables          Baseline             CPAP                                                Compression stockings                                                                 *p*
  ------------------------ -------------------- --------------------------------------------------- ------------------------------------------------------------------------------------- --------
  TST, min                 307.6 ± 83.7         321.7 ± 88.7                                        351.9 ± 107.5                                                                         0.203
  PLMI, events/h           0 (0; 0.2)           4.5 (0; 60.7)                                       8.9 (0; 74.2)[\*](#tfn11){ref-type="table-fn"}                                        0.006
  N1 sleep, % of TST       10.1 (6.9; 31.1)     10.2 (6.0; 21.4)                                    8.6 (4.3; 15.1)                                                                       0.223
  N2 sleep, % of TST       46.2 ± 8.9           43.1 ± 13.0                                         45.9 ± 13.8                                                                           0.528
  N3 sleep, % of TST       23.3 ± 12.2          25.8 ± 15.2                                         22.9 ± 11.8                                                                           0.535
  REM, % of TST            12.9 (8.8; 20.2)     17.6 (14.0; 19.7)                                   19.2 (11.3; 22.0)                                                                     0.092
  Rem latency, min         115 (81.0; 175.5)    111 (85.2; 138.8)                                   91 (64.2; 178.5)                                                                      0.794
  Arl, events/h of sleep   10.8 ± 5.8           10.7 ± 7.1                                          7.9 ± 4.7                                                                             0.192
  WASO, min                81.6 (50.1; 176.4)   82.3 (44; 112.2)                                    70.3 (45.3; 111.3)                                                                    0.135
  Minimal SaO~2~, %        85.0 (81.5; 87.2)    87.5 (80.7; 90.2)                                   83.5 (76.7; 88.0)                                                                     0.056
  Mean SaO~2~, %           93.9 ± 1.9           94.8 ± 1.8[^†^](#tfn12){ref-type="table-fn"}        93.8 ± 1.9[^‡^](#tfn13){ref-type="table-fn"}                                          0.019
  AHI, events/h            20.8 (14.2; 39.6)    7.9 (2.8; 25.4)[^†^](#tfn12){ref-type="table-fn"}   16.7 (3.5; 28.9)[\*](#tfn11){ref-type="table-fn"}[^‡^](#tfn13){ref-type="table-fn"}   0.0004
  AH time, % of TST        11.2 (6.9; 17.1)     4.3 (1.4; 10.1)[^†^](#tfn12){ref-type="table-fn"}   8.1 (2.3; 13.9)[\*](#tfn11){ref-type="table-fn"}                                      0.004
  OAI, events/h            2.9 (1.1; 10)        0.8 (0.1; 2.9)[^†^](#tfn12){ref-type="table-fn"}    1 (0; 7.2)                                                                            0.033
  CAI, events/h            0.4 (0.1; 2.4)       0.6 (0; 1.9)                                        0.2 (0; 0.9)                                                                          0.941
  REM AHI, events/h        11.4 (0.5; 19.4)     1.5 (0.5; 3.5)                                      1.8 (0; 7.1)                                                                          0.172
  Supine position, %       41.6 ± 24.6          44.9 ± 30.1                                         48.3 ± 32.8                                                                           0.654
  Supine AHI, events/h     34.1 (21.9; 50.9)    18.9 (6.5; 33.6)                                    33.6 (5.7; 42.0)                                                                      0.285

*AHI, apnea--hypopnea index; AH, apnea--hypopnea; Arl, arousals; WASO, wake after sleep onset; TST, total sleep time; SE, sleep efficiency; PLMI, periodic limb movement index; OAI, obstructive apnea index; CAI, central apnea index*.

*\*p \< 0.05 CS vs. baseline*.

*^†^p \< 0.05 CPAP vs. baseline*.

*^‡^p \< 0.05 CS vs. CPAP*.

Effect of Interventions on AHI {#S3-3}
------------------------------

The baseline AHI was 20.8 (14.2; 39.6) events/h, indicating that patients exhibited moderate OSA, and this index reduced to 7.9 (2.8; 25.4) during CPAP titration and to 16.7 (3.5; 28.9) events/h after wearing CS for 1 week (Table [2](#T2){ref-type="table"}; Figure [2](#F2){ref-type="fig"}). CS also reduced apnea-hypopnea time but increased PLMI in comparison to baseline. When limiting our analysis only to obstructive events, CPAP reduced obstructive apnea index from 2.9 (1.1, 10) to 0.8 (0.1, 2.9) events/h, *p* = 0.021 and hypopnea index from 14 (6.8, 21.9) to 2.2 (0.9, 11.6) events/h, *p* = 0.05. CPAP also increased SaO~2~. CS did not improve any of these parameters. Central apneas were virtually absent in this population, representing 0.4 (0.1, 2.4) events/h at baseline with no changes during either CS or CPAP titration.

![**Apnea--hypopnea index at baseline, with continuous positive airway pressure (CPAP) titration and while wearing compression stockings (CS)**. *N* = 14 for the three groups. ^†^*p* \< 0.004 CPAP vs. baseline; \**p* = 0.017 CS vs. baseline; ^‡^*p* = 0.017 CS vs. CPAP.](fmed-04-00057-g002){#F2}

Effect of Interventions on NC {#S3-4}
-----------------------------

There were no differences regarding NC before sleep in the three exams; however, its overnight change presented a distinct behavior: while there was an increase at baseline, CPAP and CS promoted significant reductions in NC, as shown in Table [3](#T3){ref-type="table"} and Figure [3](#F3){ref-type="fig"}.

###### 

**Data on weight, total, and segmental fluid volumes assessed before sleep (nocturnal) and their overnight variation (Δ) and NC, obtained at baseline and during CPAP titration and compression stockings (CS) use**.

                              Baseline       CPAP                                           CS                                                                              *p*
  --------------------------- -------------- ---------------------------------------------- ------------------------------------------------------------------------------- ----------
  Ultrafiltration, l/week     8.6 ± 2.3      8.8 ± 2.8                                      9.1 ± 3.0                                                                       0.524
  Dry weight, kg              77.2 ± 22.6    77.8 ± 23.2                                    78.0 ± 23.3                                                                     0.253
  Excess weight, kg           1.3 ± 1.5      1.8 ± 1.8[^†^](#tfn22){ref-type="table-fn"}    1.8 ± 1.9[\*](#tfn21){ref-type="table-fn"}                                      0.028
  ΔWeight, mg                 −5.9 ± 54      35 ± 456                                       −341 ± 570                                                                      0.057
  Nocturnal TBW, l            37.14 ± 7.99   37.23 ± 8.13                                   37.48 ± 7.81                                                                    0.740
  ΔTBW, l                     −0.04 ± 0.78   −0.16 ± 0.51                                   −0.44 ± 0.78                                                                    0.305
  Nocturnal LLW, l            12.76 ± 3.18   12.87 ± 3.32                                   12.67 ± 3.19                                                                    0.628
  Nocturnal ecLLW, % of LLW   38.5 ± 1.8     38.6 ± 2.0                                     38.2 ± 2.1                                                                      0.055
  ΔecLLW, ml                  −183 ± 72      −343 ± 220[^†^](#tfn22){ref-type="table-fn"}   −290 ± 213                                                                      0.006
  Nocturnal TW, l             17.0 ± 4.1     17.1 ± 4.1                                     17.5 ± 4.1[\*](#tfn21){ref-type="table-fn"}                                     0.030
  ΔTW, ml                     400 ± 464      414 ± 417                                      186 ± 513                                                                       0.227
  Nocturnal ecTW, % of TW     38.1 ± 1.5     38.3 ± 1.5                                     37.9 ± 1.6[^‡^](#tfn23){ref-type="table-fn"}                                    0.032
  Nocturnal NC, cm            39.9 ± 4.4     40.4 ± 4.6                                     40.4 ± 4.8                                                                      0.150
  ΔNC, cm                     0.7 ± 0.4      −1.0 ± 0.4[^†^](#tfn22){ref-type="table-fn"}   −0.4 ± 0.8[\*](#tfn21){ref-type="table-fn"}[^‡^](#tfn23){ref-type="table-fn"}   \<0.0001

*NC, neck circumference; TBW, total body water; LLW, lower limbs total water content; ecLLW, lower limbs extracellular water content; TW, trunk total water content; ecTW, trunk extracellular water content*.

*\*p \< 0.05 CS vs. baseline*.

*^†^p \< 0.05 CPAP vs. baseline*.

*^‡^p \< 0.05 CS vs. CPAP*.

![**Overnight NC variation at baseline, with CPAP titration and after wearing CS**. *N* = 14 for the three groups. CPAP, continuous positive airway pressure; CS, compression stockings; NC, neck circumference. ^†^*p* \< 0.0001 CPAP vs. baseline; \**p* = 0.001 CS vs. baseline; ^‡^*p* = 0.01 CS vs. CPAP.](fmed-04-00057-g003){#F3}

Effect of Interventions on Fluid Shift {#S3-5}
--------------------------------------

Table [3](#T3){ref-type="table"} shows a comparison of the three moments of the study protocol (baseline, CPAP titration, and after wearing CS for 1 week) regarding fluid distribution. As weight and ultrafiltration are strongly associated with fluid status in patients on dialysis, data on these parameters are also shown in Table [3](#T3){ref-type="table"}. Although estimated dry weight and ultrafiltration did not change during the study, excess weight (above predicted dry weight) was lower at baseline.

Compression stockings promoted the followings changes in body fluid distribution: they increased TW before sleep compared to baseline (*p* = 0.030), which is illustrated in Figure [4](#F4){ref-type="fig"}; they reduced extracellular TW compared to CPAP (*p* = 0.032). As TW is equal to the sum of ecTW and intracellular trunk water, this excess fluid shifted to the intracellular compartment of the trunk (Figure [5](#F5){ref-type="fig"}). CPAP did not avoid extracellular volume displacement from the legs (ΔecLLW), which was even higher than at baseline.

![**Total trunk water volume before sleep, at baseline, before polysomnography for continuous positive airway pressure (CPAP) titration, and after wearing compression stockings (CS)**. *N* = 14 for the three groups. \**p* = 0.019 CS vs. baseline.](fmed-04-00057-g004){#F4}

![**Intracellular trunk volume (relative to total trunk water) before sleep, at baseline, before polysomnography for continuous positive airway pressure (CPAP) titration, and after wearing compression stockings (CS)**. *N* = 14 for the three groups. ^‡^*p* = 0.01 CS vs. CPAP.](fmed-04-00057-g005){#F5}

Fluid shift from the legs, represented by overnight variation of ecLLW, was only significantly associated with AHI at baseline (*r*^2^ = 0.493, *p* = 0.007), as shown in Figure [6](#F6){ref-type="fig"}A. Fluid shift observed during CPAP titration and after wearing CS had no significant impact on AHI (Figures [6](#F6){ref-type="fig"}B,C, respectively).

![**Correlation between extracellular fluid shift from the legs (lower limbs extracellular water content) and apnea--hypopnea index (AHI) at baseline (A), continuous positive airway pressure (CPAP) titration (B) and compression stockings (CS) (C)**.](fmed-04-00057-g006){#F6}

Discussion {#S4}
==========

To our knowledge, this is the first study comparing overnight fluid shift and NC changes between CS and CPAP in a population on HD. We have also compared the effect of both therapies, CS and CPAP, on the severity of OSA. Our results revealed that (1) daytime use of below-the-knee CS for 1 week attenuated OSA severity in oliguric/anuric patients on HD although this effect was lower in comparison to CPAP; (2) the effects of CS were most likely attributed to displacement of fluid from the legs to the intracellular compartment of the trunk during the day, thus avoiding overnight rostral shift of extracellular fluid from the legs to the neck; (3) short-term CPAP therapy, on the other hand, did not avoid overnight fluid shift, yet it promoted a prominent reduction NC. Taken together, our findings suggest that CS may be an alternative and feasible treatment for attenuating OSA in HD patients. Furthermore, they suggest that CS and CPAP are effective on the treatment of OSA through distinct influences on overnight fluid distribution.

Obstructive sleep apnea is associated with a myriad of cardiovascular complications in the general population, such as coronary artery disease, stroke, CHF, and arterial hypertension ([@B25]--[@B28]). In patients with ESRD, who already exhibit an excessive cardiovascular risk ([@B29]), the impact of OSA can be even more devastating. Fluid overload is a possible link between high prevalence of cardiovascular disease and OSA in the setting of ESRD ([@B30]--[@B32]). Recently, hypervolemia has also been associated with more severe OSA in patients on HD ([@B33]). Indeed, there is an established background in literature in favor of fluid shift as a pathogenic factor for OSA in edematous states. In this regard, inflation of antishock trousers shifts fluid rostrally, mimicking spontaneous fluid shift and thus increasing pharyngeal resistance and narrowing the upper airway cross-sectional area in healthy individuals ([@B34]--[@B36]). In addition, magnetic resonance imaging study has shown that the severity of OSA correlates with jugular vein volume and the amount of mucosal water content surrounding the upper airway in patients on HD ([@B37]), suggesting an important role of hypervolemia in the pathogenesis of OSA in this population. In this regard, proof of concept was demonstrated by ultrafiltration without interference in uremic status in patients on HD, which attenuated OSA in this population ([@B38]).

So far, three studies have evaluated the impact of CS in individuals with preserved renal function and reported reductions in AHI from 24 to 36% ([@B14]--[@B16]). Redolfi et al. evaluated the impact of wearing CS for 1 week in patients with venous insufficiency ([@B15]), showing that despite the same body weight in both control group and after CS period, there was a 150-ml reduction in leg fluid volume after wearing CS and, more importantly, a 600-ml reduction in TBW. Therefore, less fluid was available to move rostrally, which reduced NC increase. Neither trunk volumes nor diuresis was evaluated. Nevertheless, in light of their and our findings, we can postulate that CS may avoid translocation of fluid from the trunk to the legs during the day, which increases diurnal diuresis, thus reducing TBW. In our study, patients were oliguric or anuric, and TBW was not different at baseline or after wearing CS. Still, there was a marked difference regarding fluid arrangement, once CS prevented fluid from shifting from the trunk to the legs during the day and also led to an increased intracellular TW.

To explain why intracellular TW increases after wearing CS, it is important to understand how fluid shifts according to body position. In healthy individuals, moving from recumbent to standing position, extracellular volume increases while intracellular water decreases ([@B39]). While standing up, gravitational forces exert pressure on the liquid column of the body and, consequently, hydrostatic pressure increases in the lower limbs ([@B40]). The capillary pressure in the legs when standing (90--120 cmH~2~O) exceeds the pressure needed for moving fluid to interstitial compartment (15--20 cmH~2~O) ([@B41], [@B42]). In addition, intravascular volume decreases 300--400 ml while standing ([@B43], [@B44]). Therefore, fluid shifts from intravascular and intracellular spaces, increasing extracellular volume in the lower limbs.

In this study, wearing CS prevented fluid movement from the trunk to the lower limbs and also from the intracellular to the extracellular space of the trunk. Therefore, the upward pressure exerted by CS partially counteracted gravity forces, avoiding leg swelling and keeping more fluid in the intracellular space, which is less likely to move freely to other regions of the body. Consequently, there was a reduction of the total amount of fluid reaching the neck, which partially prevented the edema buildup in upper airway during the night. This is the most likely mechanism associated with the reduction of NC and AHI while wearing CS.

Besides fluid distribution with CS, another novelty of this study was the analysis of body fluid kinetics during CPAP titration exam. We demonstrated that positive pressure exerted on upper airways had no effect on fluid shift from the legs. Still, NC reduced significantly during the night, suggesting an important reduction in upper airways edema. Therefore, regardless of excess body water volume or nocturnal fluid shift, CPAP therapy effectively abolishes obstructive events by exerting local pressure that moves fluid away from the neck, thus avoiding the upstream volume to reach upper airways, and as shown in Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}, CPAP performed significantly better than CS for both reduction of AHI and overnight change in NC. Finally, the mechanisms involved in the reduction of both AHI and NC by CS and CPAP are completely different: the former interferes in fluid redistribution during the night, while the latter prevents fluid reaching the neck.

This study has strengths and limitations. The main strengths were the randomized and crossover study design, as well as the use of multifrequency BIS, which allowed us to precisely estimate total, extracellular, and intracellular fluid volumes in each body segment. We also provided a novelty by demonstrating that CS can alleviate OSA in patients on HD. In addition, new insights regarding the physiology involved in the overnight fluid shift contributed to elucidate the mechanisms of action of CS and CPAP therapy. One of the limitations of this study was the small sample size, which makes the study prone for both type I and II errors. Another limitation was the non-precise assessment of residual diuresis volume, although most patients were anuric. Even though the referred urinary output was estimated (and not measured) to be lower than 200 ml per episode, this information is likely to be accurate since there is a trend toward a lower bladder reservoir in patients with long dialysis vintage ([@B45]). The NC measurement is also prone to error, although there is no gold standard method to access it. Finally, this study is a short-term clinical trial. Our main focuses were the mechanisms of fluid kinetics during the night in three different situations. To ascertain the clinical outcomes of both CPAP and CS therapies in this population, a longer treatment period for each of these treatments would be necessary. Therefore, further studies are required to evaluate adherence and long-term effect of CS and CPAP on OSA in HD patients.

In conclusion, CS and short-term CPAP can alleviate OSA in patients on HD by two different predominant mechanisms. While CS exert pressure on the lower limbs, maintaining fluid in the intracellular compartment of the trunk, CPAP therapy had no action on fluid shift, yet prevented it from reaching the neck. Even though the effect of CS is inferior to the standard CPAP treatment, CS may be an alternative and feasible treatment to attenuate OSA in HD patients. Moreover, the association of these two treatments can be useful to treat OSA and requires further investigation on ESRD patients.
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